A study of Montelukast compared with placebo in pediatric patients with episodic asthma

The goal of this study is to evaluate the effects of an FDA-approved asthma drug in children 1 to 5 years of age with episodic asthma. The study will include seven visits and will last approximately one year.

Your child may be eligible to participate in this study if he or shet:

• Is 1 to 5 years of age
• Has episodic (periodic) asthma symptoms (e.g., wheezing, shortness of breath)

This is a partial list of eligibility requirements. To inquire about your child's eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.